Page 29 - Test PDF v5

« Back to Contents ENDOMETRIAL CANCER

LiFE re

Literature for ENYGO

Medical treatment of recurrent endometrial cancer

Editor Ewa Surynt German gynaecological departments between 2006 and 2013 at
three different time points.
Descriptive summary
The major findings of this survey were: Progestins are the most
During the period covered by the third edition of the LiFE report, commonly used endocrine agents in 2013 (79.8 %). Diverse chemo-
medical treatment of recurrent uterine malignancies was discussed therapy regimen were used, but 65.3 of the participants responded
in two articles. that they used platinum. Local recurrence and distant metastasis of
EC were often treated with surgery and radiotherapy and subgroup
Han et al. retrospectively analysed 4 patients with advanced or analyses only depicted differences in the preferred endocrine and
recurrent uterine sarcoma, treated with bevacizumab (BEV) and cytostatic drugs, when stratified for hospital. Authors concluded that
chemotherapy. The chemotherapeutic drugs included dacarbazine the lack of preferred cytostatic drug might be the result of inconsi-
(DTIC), cisplatin (DDP), etoposide (VP-16), adriamycin, paclitaxel, stent and limited literature not providing a real standard of care in
and carboplatin. The mean number of cycles was 8.3 (range 4–12 recurrent and metastatic EC.
cycles). Of the 4 patients, 1 achieved complete response (CR), with a
disease-free survival time of 96 months; 1 achieved partial response Please see the report by K. Zalewski “Medical treatment of recurrent
(PR), with progression-free survival (PFS) of 13 months and overall ovarian cancer,” on the activity and toxicity of mTOR inhibitor temsi-
survival (OS) of 25 months; 1 achieved stable disease (SD), with rolimus in patients with advanced/recurrent EC.
PFS of 9 months and OS of 24 months; and 1 developed progressive
disease, with PFS of 3 months and OS of 9 months. The response
rate was 50 %, and the clinical benefit rate [CR + PR+ SD] was 75 %.
Treatment-related adverse reactions occurred in all 4 patients, inc-
luding bone marrow suppression and gastrointestinal reactions. One
patient developed grade 4 thrombocytopenia, whereas the remaining
3 patients developed grade 2 leukopenia. Authors concluded that
BEV combined with chemotherapy exhibits efficacy in the treatment
of advanced or recurrent uterine sarcomas, with a tolerable toxicity
profile, and may be considered as a safe and effective candidate tre-
atment for this type of tumour, however, the extremely small sample
size and the retrospective design challenge these conclusions.

On the background of contradictory and inconclusive recommendati-
ons on the treatment of recurrent and metastatic endometrial cancer,
Battista et al. studied the pattern of care in more than 700 different

Relevant articles retrieved Nov 2015 - Feb 2016

NPoleaTsitele, see the next page Authors Journal Link to abstract
Mol Clin Oncol.
1 Curative effect of bevacizumab combined with chemotherapy in advanced or Han Y et al. http://www.ncbi.nlm.nih.gov/
recurrent uterine sarcoma. Arch Gynecol Obstet. pubmed/26893869

2 Management of recurrent or metastatic endometrial cancer in Germany: Battista MJ et al. http://www.ncbi.nlm.nih.gov/
results of the nationwide AGO pattern of care studies from the years 2013, pubmed/26099624
2009 and 2006.

International Journal of Gynecological Cancer, Volume 26, Supplement #1 Page 29